Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Flerie ABFRA:1NP1 37 PB Ratio is 0.51 as of Jul. 26, 2026, which is 69% below its 10-year median of 1.67. GuruFocus rates FRA:1NP1 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,231 Biotechnology companies, Flerie AB ranks better than 93.34% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-26), Flerie AB's share price is €1.81. Flerie AB's Book Value per Share for the quarter that ended in Jun. 2026 was €3.57. Hence, Flerie AB's PB Ratio of today is 0.51.
Good Sign:
Flerie AB stock PB Ratio (=0.53) is close to 2-year low of 0.51.
The historical rank and industry rank for Flerie AB's PB Ratio or its related term are showing as below:
FRA:1NP1'
s PB Ratio Range Over the Past 10 Years
Min: 0.04 Med: 1.67 Max: 24.76
Current: 0.53
During the past 12 years, Flerie AB's highest PB Ratio was 24.76. The lowest was 0.04. And the median was 1.67.
FRA:1NP1's PB Ratio is ranked better than 93.34% of 1231
companies
in the Biotechnology industry
Industry Median: 2.77
vs FRA:1NP1: 0.53
During the past 12 months, Flerie AB's average Book Value Per Share Growth Rate was -19.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.40% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Flerie AB was 271.50% per year. The lowest was -31.70% per year. And the median was 11.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Flerie AB PB Ratio Related Terms
Flerie AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Flerie AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Flerie AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Flerie AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Flerie AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Flerie AB (FRA:1NP1) has a PB Ratio of 0.51 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Flerie AB and its competitors. This is 69% below median its historical median of 1.67. Over the past decade, Flerie AB's PB Ratio has ranged from 0.04 to 24.76. According to the industry distribution chart, Flerie AB ranks #82 out of 1231 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Flerie AB's PB Ratio too high?
Flerie AB's current PB Ratio of 0.51 is 69% below median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 24.76. The Biotechnology industry median PB Ratio is 2.77. Flerie AB's value of 0.51 is 81.6% below this industry median. Based on the distribution chart, Flerie AB ranks #82 out of 1231 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Flerie AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #82 out of 1231 companies for PB Ratio. This places Flerie AB in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.77. Flerie AB's value of 0.51 is 81.6% below this benchmark. Historically, Flerie AB's own PB Ratio has ranged from 0.04 to 24.76 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 2.77, Flerie AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Flerie AB's current PB Ratio of 0.51 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current PB Ratio is 0.51, which is 69% below median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current PB Ratio of 0.51. The current PB Ratio is 0.51, which is 69% below median its 10-year median of 1.67 and 81.6% below the Biotechnology industry median of 2.77. Flerie AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current PB Ratio is 0.51 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
37GF Score
Get the complete analysis for FRA:1NP1
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
